Tislelizumab Plus GemOx in Patients with Relapsed/Refractory Classic Hodgkin Lymphoma: A Single-Arm, Multi-Center Phase II Trial
文献类型：期刊论文
| 作者 | Ding, Kaiyang2; Liu, Hailing1,3; Yang, Haiyan4; Cao, Lei1,3 ; Zhao, Xiaoli1; Wu, Wei1,3; Zhang, Xiaoyan1,3; Wang, Li1,3; Xu, Wei1,3; Zhu, Huayuan1,3
|
| 刊名 | BLOOD
 |
| 出版日期 | 2021-11-23 |
| 卷号 | 138 |
| ISSN号 | 0006-4971 |
| DOI | 10.1182/blood-2021-150145 |
| WOS研究方向 | Hematology |
| 语种 | 英语 |
| 出版者 | AMER SOC HEMATOLOGY |
| WOS记录号 | WOS:000736398805113 |
| 源URL | [http://ir.hfcas.ac.cn:8080/handle/334002/131812]  |
| 专题 | 中国科学院合肥物质科学研究院 |
| 作者单位 | 1.Nanjing Med Univ, Collaborat Innovat Ctr Personalized Canc Med, Jiangsu Key Lab Canc Biomarkers Prevent & Treatme, Nanjing, Peoples R China 2.Univ Sci & Technol China, Affiliated Hosp 1, Anhui Prov Hosp, Dept Hematol, Hefei, Peoples R China 3.Nanjing Med Univ, Affiliated Hosp 1, Jiangsu Prov Hosp, Dept Hematol, Hefei, Peoples R China 4.Univ Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp, Dept Med Oncol, Hangzhou, Peoples R China |
| 推荐引用方式 GB/T 7714 | Ding, Kaiyang,Liu, Hailing,Yang, Haiyan,et al. Tislelizumab Plus GemOx in Patients with Relapsed/Refractory Classic Hodgkin Lymphoma: A Single-Arm, Multi-Center Phase II Trial[J]. BLOOD,2021,138. |
| APA | Ding, Kaiyang.,Liu, Hailing.,Yang, Haiyan.,Cao, Lei.,Zhao, Xiaoli.,...&Fan, Lei.(2021).Tislelizumab Plus GemOx in Patients with Relapsed/Refractory Classic Hodgkin Lymphoma: A Single-Arm, Multi-Center Phase II Trial.BLOOD,138. |
| MLA | Ding, Kaiyang,et al."Tislelizumab Plus GemOx in Patients with Relapsed/Refractory Classic Hodgkin Lymphoma: A Single-Arm, Multi-Center Phase II Trial".BLOOD 138(2021). |
入库方式： OAI收割
来源：合肥物质科学研究院
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。